Fintel reports that on October 25, 2024, Maxim Group initiated coverage of reAlpha Tech (NasdaqCM:AIRE) with a Buy ...

Fintel reports that on October 25, 2024, Maxim Group upgraded their outlook for Annovis Bio (NYSE:ANVS) from Hold to Buy. ...

Maxim Group analyst Michael Diana maintained a Hold rating on Westamerica Bancorporation (WABC – Research Report) yesterday. The ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M.

To attend, just sign up to become an M-Vest member and stay tuned for more updates. Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New ...

On Monday, Hain Celestial Group Inc (HAIN) stock saw a decline, ending the day at $8.75 which represents a decrease of $-0.17 or -1.91% from the prior close of $8.92. The stock opened at $8.92 and ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) (”Applied DNA”), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in ...

Maxim Group initiated coverage on GameSquare Holdings Inc (NASDAQ: NASDAQ:GAME) with a Buy rating and a price target of $3.00. The firm cited the company's compelling valuation as a key reason for ...

Tuesday, Maxim (NASDAQ:MXIM) Group began coverage on shares of Ocugen, Inc. (NASDAQ: NASDAQ:OCGN), issuing a Buy rating and setting a price target of $4.00. The firm highlighted Ocugen's financial ...

Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Maxim (NASDAQ:MXIM) Group initiated coverage on GameSquare Holdings Inc (NASDAQ: NASDAQ:GAME) with a Buy rating and a price target of $3.00. The firm cited the company's compelling valuation as a key ...